Calidi Biotherapeutics effects 1-for-12 reverse stock split effective August 4, 2025

Calidi Biotherapeutics, Inc.

Reverse stock split at ratio 1-for-12 became effective on August 4, 2025.
No fractional shares issued; rounding up to nearest whole share; authorized shares unchanged at 330M common, 1M preferred.
Stock continues trading under symbol CLDI on NYSE American with new CUSIP 320703408.
Company states reverse split aims to optimize market dynamics and broaden investor appeal.
All outstanding equity awards adjusted proportionally to reflect the reverse stock split.

item 3.03item 5.03item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.